🚀 VC round data is live in beta, check it out!
Neogen Valuation Multiples
Discover revenue and EBITDA valuation multiples for Neogen and similar public comparables like Dr. Lal PathLabs, Tecan Group, Fleury, BGI Genomics and more.
Neogen Overview
About Neogen
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
Founded
1981
HQ
Employees
975
Website
Sectors
Financials (LTM)
EV
$3B
Neogen Financials
Neogen reported last 12-month revenue of $858M and EBITDA of $173M.
In the same LTM period, Neogen generated $407M in gross profit, $173M in EBITDA, and had net loss of ($175M).
Revenue (LTM)
Neogen P&L
In the most recent fiscal year, Neogen reported revenue of $895M and EBITDA of ($936M).
Neogen expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $858M | XXX | $895M | XXX | XXX | XXX |
| Gross Profit | $407M | XXX | $421M | XXX | XXX | XXX |
| Gross Margin | 47% | XXX | 47% | XXX | XXX | XXX |
| EBITDA | $173M | XXX | ($936M) | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | (105%) | XXX | XXX | XXX |
| EBIT Margin | (22%) | XXX | (0%) | XXX | XXX | XXX |
| Net Profit | ($175M) | XXX | ($1B) | XXX | XXX | XXX |
| Net Margin | (20%) | XXX | (122%) | XXX | XXX | XXX |
| Net Debt | — | — | $765M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Neogen Stock Performance
Neogen has current market cap of $2B, and enterprise value of $3B.
Market Cap Evolution
Neogen's stock price is $10.80.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $2B | 14.8% | XXX | XXX | XXX | $-5.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNeogen Valuation Multiples
Neogen trades at 3.5x EV/Revenue multiple, and 17.3x EV/EBITDA.
EV / Revenue (LTM)
Neogen Financial Valuation Multiples
As of April 4, 2026, Neogen has market cap of $2B and EV of $3B.
Equity research analysts estimate Neogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Neogen has a P/E ratio of (13.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 17.3x | XXX | (3.2x) | XXX | XXX | XXX |
| EV/EBIT | (16.2x) | XXX | (1788.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 7.4x | XXX | 7.1x | XXX | XXX | XXX |
| P/E | (13.5x) | XXX | (2.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (64.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Neogen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Neogen Margins & Growth Rates
Neogen's revenue in the last 12 month grew by 1%.
Neogen's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.4M for the same period.
Neogen Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | (105%) | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 99% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 20% | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 28% | XXX | 24% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Neogen Public Comps
See public comps and valuation multiples for other Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Dr. Lal PathLabs | XXX | XXX | XXX | XXX | XXX | XXX |
| Tecan Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Fleury | XXX | XXX | XXX | XXX | XXX | XXX |
| BGI Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Genscript Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Neogen M&A Activity
Neogen acquired XXX companies to date.
Last acquisition by Neogen was on XXXXXXXX, XXXXX. Neogen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Neogen
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNeogen Investment Activity
Neogen invested in XXX companies to date.
Neogen made its latest investment on XXXXXXXX, XXXXX. Neogen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Neogen
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Neogen
| When was Neogen founded? | Neogen was founded in 1981. |
| Where is Neogen headquartered? | Neogen is headquartered in United States. |
| How many employees does Neogen have? | As of today, Neogen has over 975 employees. |
| Who is the CEO of Neogen? | Neogen's CEO is Mikhael Nassif. |
| Is Neogen publicly listed? | Yes, Neogen is a public company listed on Nasdaq. |
| What is the stock symbol of Neogen? | Neogen trades under NEOG ticker. |
| When did Neogen go public? | Neogen went public in 1989. |
| Who are competitors of Neogen? | Neogen main competitors are Dr. Lal PathLabs, Tecan Group, Fleury, BGI Genomics. |
| What is the current market cap of Neogen? | Neogen's current market cap is $2B. |
| What is the current revenue of Neogen? | Neogen's last 12 months revenue is $858M. |
| What is the current revenue growth of Neogen? | Neogen revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Neogen? | Current revenue multiple of Neogen is 3.5x. |
| Is Neogen profitable? | Yes, Neogen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Neogen? | Neogen's last 12 months EBITDA is $173M. |
| What is Neogen's EBITDA margin? | Neogen's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Neogen? | Current EBITDA multiple of Neogen is 17.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.